AiCuris Logo
cekom
  • Home
  • About AiCuris
    • Company Profile
    • Leadership
    • Memberships
  • PREP
    • PREP
    • AIC649 in Corona
    • AMR
    • AiCubator
    • Partnering & Licensing
  • Research & Development
    • Strategy
    • R&D Pipeline
    • Projects Overview
    • Pritelivir Early Access
    • Research Tools & Services
  • Partnering & Licensing
    • AiCuris & Partnering
    • Partnering Opportunities
      • Pritelivir (AIC316)
      • AIC649
    • In-Licensing & Collaborations
    • AiCubator
  • News & Media
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017 and before
    • Services for Press
    • Deutscher Zukunftspreis - 2018 Award Winners
    • EFPIA Disclosure Code
  • Career
    • Join AiCuris
    • Employee Benefits
    • Job Opportunities
    • Privacy Notice for applicants
  • Contact
    • Directions
  • AiCuris & Partnering
  • Partnering Opportunities
    • Pritelivir (AIC316)
    • AIC649
  • In-Licensing & Collaborations
  • AiCubator

Current opportunities:

The following compounds are currently open for out licensing and/or co-development with a strategic partner:

 

HSV Pritelivir (AIC316)

Pritelivir - The perfect solution for resistant HSV infections at immunocompromised patients.

AIC649

AIC649 - Proprietary Immune Modulator and Potential Cure for Chronic Hepatitis B Infection

 

If you have further questions please contact us

  • Imprint
  • Privacy notice